<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OXAZEPAM - oxazepam capsule </strong><br>REMEDYREPACK INC. <br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>Oxazepam is the first of a chemical series of compounds, the 3-hydroxybenzodiazepinones. A therapeutic agent providing versatility and flexibility in control of common <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span>, this product exerts prompt action in a wide variety of disorders associated with <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> associated with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. In tolerance and toxicity studies on several animal species, this product reveals significantly greater safety factors than related compounds (chlordiazepoxide and diazepam) and manifests a wide separation of effective doses and doses inducing side effects.<br>Oxazepam is 7 chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one and has the following structural formula:<br><div class="Figure"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=52488349-1c84-4cdc-89d1-c841a68e904f&amp;name=MM1.jpg"></div>
<br><br>Oxazepam is a white crystalline powder.<br>Each capsule for oral administration contains 10 mg, 15 mg or 30 mg of oxazepam.<br>Inactive ingredients: hypromellose, lactose (monohydrate), magnesium stearate and corn starch. The capsule shells and imprinting inks contain: gelatin, titanium dioxide, shellac, black iron oxide, propylene glycol and D&amp;C Red #7 Calcium Lake E180. The 10 mg capsules also contain: methylparaben, butylparaben, propylparaben, benzyl alcohol, sodium propionate, edetate calcium disodium and sodium lauryl sulfate. The 15 mg ink also contains: D&amp;C Yellow #10 Aluminum Lake. The 30 mg ink also contains: FD&amp;C Red #40 Aluminum Lake #129 and FD&amp;C Blue #2 Aluminum Lake #132.<br><br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>Pharmacokinetic testing in 12 volunteers demonstrated that a single 30 mg dose of a capsule, tablet or suspension will result in an equivalent extent of absorption. For the capsule and tablet, peak plasma levels averaged 450 mg/mL and were observed to occur about 3 hours after dosing. The mean elimination half-life for oxazepam was approximately 8.2 hours (range 5.7 to 10.9 hours).<br>This product has a single, major inactive metabolite in man, a glucuronide excreted in urine.<br>Age (&lt;80 years old) does not appear to have a clinically significant effect on oxazepam kinetics. A statistically significant increase in elimination half-life in the very elderly (&gt;80 years of age) as compared to younger subjects has been reported, due to a 30% increase in volume of distribution, as well as a 50% reduction in unbound clearance of oxazepam in the very elderly. (see<span class="Underline">PRECAUTIONS: Geriatric Use</span>).<br><br>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-3"></a><p></p>
<h1>ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY</h1>In mice, oxazepam exerts an anticonvulsant (anti-pentylenetetrazol) activity at 50-percent-effective doses of about 0.6 mg/kg orally. (Such anticonvulsant activity of benzodiazepines correlates with their tranquilizing properties.) To produce <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (rotabar test) and sedation (abolition of spontaneous motor activity), the 50-percent-effective doses of this product are greater than 5 mg/kg orally. Thus, about ten times the therapeutic (anticonvulsant) dose must be given before <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> ensues, indicating a wide separation of effective doses and doses inducing side effects.<br>In evaluation of antianxiety activity of compounds, conflict behavioral tests in rats differentiate continuous response for food in the presence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>-provoking stress (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) from drug-induced motor <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>. This product shows significant separation of doses required to relieve <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and doses producing sedation or <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span>-producing doses exceed those of related CNS-acting drugs.<br>Acute oral LD50 in mice is greater than 5000 mg/kg, compared to 800 mg/kg for a related compound (chlordiazepoxide).<br>Subacute toxicity studies in dogs for four weeks at 480 mg/kg daily showed no specific changes; at 960 mg/kg, two out of eight died with evidence of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. This wide margin of safety is significant compared to chlordiazepoxide HCl, which showed nonspecific changes in six dogs at 80 mg/kg. On chlordiazepoxide, two out of six died with evidence of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> at 127 mg/kg, and six out of six died at 200 mg/kg daily. Chronic toxicity studies of oxazepam in dogs at 120 mg/kg/day for 52 weeks produced no toxic manifestation.<br>Fatty metamorphosis of the liver has been noted in six-week toxicity studies in rats given this product at 0.5% of the diet. Such accumulations of fat are considered reversible, as there is no <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> or <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. Breeding studies in rats through two successive litters did not produce fetal abnormality.<br>Oxazepam has not been adequately evaluated for mutagenic activity.<br>In a carcinogenicity study, oxazepam was administered with diet to rats for two years. Male rats receiving 30 times the maximum human dose showed a statistical increase, when compared to controls, in benign thyroid follicular cell tumors, testicular interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>, and <span class="product-label-link" type="condition" conceptid="4052054" conceptname="Benign adenoma of prostate">prostatic adenomas</span>. An earlier published study reported that mice fed dietary dosages of 35 or 100 times the human daily dose of oxazepam for 9 months developed a dose-related increase in liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>.1 In an independent analysis of some of the microscopic slides from this mouse study, several of these tumors were classified as <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span>. At this time, there is no evidence that clinical use of oxazepam is associated with tumors.<br><br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>Oxazepam is indicated for the management of <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> or for the short-term relief of the symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> or <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> associated with the stress of everyday life usually does not require treatment with an anxiolytic.<br><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> associated with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is also responsive to oxazepam therapy.<br>This product has been found particularly useful in the management of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> in older patients.<br>Alcoholics with acute <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>, inebriation, or with <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> associated with alcohol withdrawal are responsive to therapy.<br>The effectiveness of oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.<br><br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>History of previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to oxazepam. Oxazepam is not indicated in psychoses.<br><br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>As with other CNS-acting drugs, patients should be cautioned against driving automobiles or operating dangerous machinery until it is known that they do not become drowsy or dizzy on oxazepam therapy.<br>Patients should be warned that the effects of alcohol or other CNS-depressant drugs may be additive to those of oxazepam, possibly requiring adjustment of dosage or elimination of such agents.<br><br><span class="Bold">Physical and Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span><br></span>Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>), have occurred following abrupt discontinuance of oxazepam. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage-tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving oxazepam or other psychotropic agents because of the predisposition of such patients to <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span> and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.<br><br><span class="Bold">USE IN PREGNANCY<br>An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobramate) during the first trimester of pregnancy has been suggested in several studies. Oxazepam, a benzodiazepine derivative, has not been studied adequately to determine whether it, too, may be associated with an increased risk of fetal abnormality. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant, they should communicate with their physician about the desirability of discontinuing the drug.</span><br><br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<span class="Bold">General<br></span>Although <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has occurred only rarely, oxazepam should be administered with caution to patients in whom a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> might lead to cardiac complications. This is particularly true in the elderly patient.<br><br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>To assure the safe and effective use of oxazepam, patients should be informed that, since benzodiazepines may produce psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.<br><br>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-9"></a><p></p>
<h1>PEDIATRIC USE</h1>Safety and effectiveness in pediatric patients under 6 years of age have not been established. Absolute dosage for pediatric patients 6 to 12 years of age is not established.<br><br>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-10"></a><p></p>
<h1>GERIATRIC USE</h1>Clinical studies of oxazepam were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects. Age (&lt;80 years old) does not appear to have a clinically significant effect on oxazepam kinetics (see<span class="Underline">CLINICAL PHARMACOLOGY</span>).<br>Clinical circumstances, some of which may be more common in the elderly, such as hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, should be considered. Greater sensitivity of some older individuals to the effects of oxazepam (e.g., sedation, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, paradoxical excitation) cannot be ruled out (see<span class="Underline">PRECAUTIONS: General<span class="Underline">ADVERSE REACTIONS</span>). In general, dose selection for oxazepam for elderly patients should be cautious, usually starting at the lower end of the dosing range (see<span class="Underline">DOSAGE AND ADMINISTRATION</span>).<br><br></span>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-11"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<br>Other side effects occurring during oxazepam therapy include rare instances of minor diffuse <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>-morbilliform, urticarial, and maculopapular, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and altered libido. Such side effects have been infrequent and are generally controlled with reduction of dosage. A case of an extensive <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed drug eruption</span> also has been reported.<br>Although rare, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> have been reported during therapy. Periodic blood counts and liver-function tests are advisable. <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span> with oxazepam has been reported in rare instances and does not appear to be specifically related to dose or age.<br>Although the following side reactions have not as yet been reported with oxazepam, they have occurred with related compounds (chlordiazepoxide and diazepam): paradoxical excitation with severe <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">rage</span> reactions, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, menstrual irregularities, change in EEG pattern, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> including <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>.<br>Transient <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> or <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span> has been reported in association with the use of benzodiazepines.<br><br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-12"></a><p></p>
<h1>OVERDOSAGE</h1>In the management of overdosage with any drug, it should be born in mind that multiple agents may have been taken.<br><br><span class="Bold">Symptoms<br></span>Overdosage of benzodiazepines is usually manifested by varying degrees of central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. In mild cases, symptoms include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>. In more serious cases, and especially when other drugs or alcohol were ingested, symptoms may include <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, hypnotic state, stage one (1) to three (3) <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and very rarely, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<br><br><span class="Bold">Management<br></span>Induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or gastric lavage should be undertaken, followed by general supportive care, monitoring of vital signs, and close observation of the patient. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, though unlikely, usually may be controlled with norepinephrine bitartrate injection. The value of dialysis has not been adequately determined for oxazepam.<br>The benzodiazepine antagonist flumazenil may be used in hospitalized patients as an adjunct to, not as a substitute for, proper management of benzodiazepine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. The prescriber should be aware of a risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. The complete flumazenil package insert includingCONTRAINDICATIONS,WARNINGS,andPRECAUTIONSshould be consulted prior to use.<br><br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-13"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>Because of the flexibility of this product and the range of <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span> responsive to it, dosage should be individualized for maximum beneficial effects.<br><br>OXAZEPAMUsual DoseMild-to-moderate <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, with associated <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> or related symptoms of functional origin or secondary to organic disease10 to 15 mg, 3 or 4 times dailySevere <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> syndromes, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> associated with depression15 to 30 mg, 3 or 4 times dailyOlder patients with <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and agitationInitial dosage: 10 mg, 3 times daily. If necessary, increase cautiously to 15 mg, 3 or 4 times dailyAlcoholics with acute inebriation, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> on withdrawal15 to 30 mg, 3 or 4 times dailyThis product is not indicated in pediatric patients under 6 years of age. Absolute dosage for pediatric patients 6 to 12 years of age is not established.<br><br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>Oxazepam Capsules, USP are available as:<br>10 mg: white capsules, imprinted GG 505 in black and pink ink bands and are supplied as:<br>NDC 0781-2809-01 bottles of 100 capsules<br>NDC 0781-2809-05 bottles of 500 capsules<br>NDC 0781-2809-10 bottles of 1000 capsules<br>15 mg: white capsules, imprinted GG 506 in black and red ink bands and are supplied as:<br>NDC 0781-2810-01 bottles of 100 capsules<br>NDC 0781-2810-05 bottles of 500 capsules<br>NDC 0781-2810-10 bottles of 1000 capsules<br>30 mg: white capsules, imprinted GG 507 in black and maroon ink bands and are supplied as:<br>NDC 0781-2811-01 bottles of 100 capsules<br>NDC 0781-2811-05 bottles of 500 capsules<br>NDC 0781-2811-10 bottles of 1000 capsules<br><br>Store at 20(68[see USP Controlled Room Temperature]. Protect from moisture.<br>Dispense in a tight, light-resistant container.<br><br>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-15"></a><p></p>
<h1>REFERENCES</h1>1.  FOX, K.A., LAHCEN, R.B.: Liver-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">Adenomas</span> and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">Peliosis Hepatis</span> in Mice Associated with Oxazepam. Res. Commun. Chem. Pathol. Pharmacol. 8:481-488, 1974.<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>DRUG: Oxazepam<br>GENERIC: Oxazepam<br>DOSAGE: CAPSULE<br>ADMINSTRATION: ORAL<br>NDC: 49349-715-02<br>STRENGTH:10 mg<br>COLOR: white<br>SHAPE: CAPSULE<br>SCORE: No score<br>SIZE: 14 mm<br>IMPRINT: 30<br>QTY: 30<br><br><div class="Figure"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=52488349-1c84-4cdc-89d1-c841a68e904f&amp;name=MM2.jpg"></div>
<br><br><div class="Figure"><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=52488349-1c84-4cdc-89d1-c841a68e904f&amp;name=MM3.jpg"></div>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXAZEPAM 		
					</strong><br><span class="contentTableReg">oxazepam capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-715(NDC:0781-2809)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXAZEPAM</strong> (OXAZEPAM) </td>
<td class="formItem">OXAZEPAM</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 7</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE CALCIUM DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PROPIONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GG505</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-715-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071813</td>
<td class="formItem">09/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>455a4c6c-db51-4e15-9a84-a243e9ca1be9</div>
<div>Set id: 52488349-1c84-4cdc-89d1-c841a68e904f</div>
<div>Version: 1</div>
<div>Effective Time: 20110906</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
